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tion, where MoH achieves equity principles by enhancing access to medicine among 
the poor, while pharmaceutical companies launch their products in the Egyptian 
market, with an acceptable return to their investments.
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Objectives: Japan is a low generic adoption market, and increased penetration has 
become a critical target to generate savings to fund innovative drugs and control 
healthcare expenditure. The objective of this research was to provide an overview 
of policies implemented in Japan to boost generics uptake and to assess impact of 
these measures. MethOds: Generics policies and uptake were identified through 
literature review from: Japanese authority website, Japan Generics Association 
website, Medline®, ICHUSHI® database and grey literature. Results: Generics 
policies have been implemented in Japan since 2002. In 2002, the National Health 
Insurance (NHI) medical fee schedule introduced financial incentives to prescribe 
generic drugs for providers (pharmacies and hospitals). Since then, various financial 
incentives to providers have been introduced by the biannual revision of NHI medi-
cal fee schedule. Diagnostic Procedure Classification system (bundled payment) 
encouraging generic drug use was introduced in acute care hospitals in 2003 and 
expanded to 21% of general hospitals (55% of hospital beds) in 2014. In 2007, the 
government put in place an action plan to encourage generic drug use. This was 
complemented in 2013 by a roadmap aiming at increased generic penetration to 
exceed 60% by 2018. More aggressive financial incentives were introduced in April 
2014 setting up generic volume threshold for pharmacies. The generic market share 
was continuously increased from 32.5% (2005), 39.9% (2011), to 47.9% (2013), and 
rapidly increased from 51.2% (March 2014) to 57.1% (November 2014). The recent 
policy accelerating the generic market share targeting at least 70% by 2017 is under 
discussion at the economic advisory council and raise concern about excessive 
speed. cOnclusiOns: The recent health policy measures to increase generics 
uptake confirm this priority for policy decision makers in Japan. Following recent 
aggressive policies the Japanese generic market will soon match other developed 
countries.
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Objectives: Regarding the discussion on AMNOG in Germany that for certain 
diseases it might be more difficult to prove an additional benefit (AB) than for 
other ones, a respective analysis of benefit assessments was conducted consider-
ing the following disease categories: Chronic conditions, cancer, and infectious 
diseases. MethOds: In total, 91 benefit assessments finalized until 31 December 
2014 (except for drugs integrated into an existing reference price group) and entail-
ing 182 patient groups (PG) were analyzed. Results: A total of 41 benefit assess-
ments regarding chronic conditions entailing 89 PG (of which 52 were part of 
antidiabetic drug assessments) were conducted. An AB vs. the appropriate com-
parator could not be proven for 83% of PG. For antidiabetic drugs, this number even 
amounted to 90% (47 of 52 PG). A considerable AB was granted for only 2% of PG 
(Ticagrelor for NSTEMI patients and Belimumab for systemic lupus erythematosus 
with high disease activity). As opposed to chronic conditions, the proportions 
of PG without any AB were only 46% and 39% in cancer and infectious diseases, 
respectively. A considerable AB was granted for 28% und 18% of PG, respectively. In 
terms of assessments, no AB was granted for any PG in case of 30 (73%) out of 41 
benefit assessments regarding drugs for chronic conditions (including 11 out of 15 
assessments for antidiabetic drugs). As opposed to this, there was no AB acknowl-
edged in only 3 (27%) out of 11 assessments on drugs against infectious diseases 
and in only 5 (22%) out of 23 assessments on anticancer drugs. cOnclusiOns: 
There seems to be a correlation between disease category and the chance of AB 
recognition. Reasons for this could be the choice of an appropriate comparator 
as well as issues regarding patient-relevant endpoints. These results could be 
relevant discussing the further development of AMNOG.
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Objectives: the aim of this study was to identify the cohort of patients starting 
treatment with biologics in the years 2012-2013 and estimate the number of patients 
that switch therapy within the first 12 months. MethOds: Patients were enrolled 
based on data extrapolated from the File F and H- OSP File (Administrative data-
base) of the Lazio region (central region in Italy). The treatment-naïve patients has 
been defined as individuals who did not have a prescription in the two years before 
the index prescription. Patients that switch biologic therapy have been defined 
as therapeutic prescription different than Anatomical Therapeutic Chemical clas-
sification (ATC) of enrollment within one year of the index date. Biologic drug, 
hospitalization and concomitant drug cost have been included in the analysis. The 
information sources were linked with a deterministic record linkage and the patho-
logical condition was inferred from the treatment plan prescription of the Lazio 
Region. Results: From a total number of 33,027 patients treated with biologic 
drug between 2010-2014 in the Lazio region, it were estimated 3,002 treatment-
naïve patients (43% male). The most frequent prescription was related to Etanercept 
(974 patients, 32%), adalimumab (898 patients, 30%) and infliximab (524 patients, 
Objectives: The National Committee for Technology Incorporation (CONITEC) aims 
to support Ministry of Health in decisions on incorporation, exclusion or modi-
fication of technologies in the Brazilian Public Health System (SUS). For this, it 
produces reports with recommendations with different characteristics. To analyze 
the CONITEC reports on incorporation, exclusion or modification of health technolo-
gies in the SUS. MethOds: Descriptive study, based on the reports available at the 
CONITEC website, from July 2012 to April 2015. Reports were classified according to: 
type of technology, type of applicant, type of report, presence of Health Economic 
Evaluation (HEE), and the type of HEE. Results: One hundred and thirty two reports 
were analyzed. The type of technologies most frequently evaluated were: drugs 
(65.2%), procedures (19.7%) and materials (9.1%). The two major applicants were: 
Public Health System (51.5%) and pharmaceutical industry (37.1%). The majority of 
reports were classified as: Description of Technology (40%), Mini Health Technology 
Assessment (33%), Rapid Review (23%) and only 4% of the reports were Full Health 
Technology Assessment. One hundred and one reports studies included some eco-
nomic data, 53.5% (n = 54) were classified as partial HEE and 46.5% (n = 47) were 
full HEE. Among partial economic evaluation, initial estimates of budget impact 
analysis was the most frequent (n = 51; 94.4%) and among the full economic evalu-
ations, cost-effectiveness analysis (n = 20; 42.6%). Out of 47 full economic evalua-
tions, 33 (70.2%) presented the incremental cost-effectiveness ratios (ICERs). Of all 
the analyzed reports (n = 132), only 25% (n = 33) performed a complete HEE with 
ICER. cOnclusiOns: The type of technologies most frequently evaluated were 
drugs, and the major applicant was the Public Health System. The majority of the 
recommendations were based on Technology Description reports, and the most 
common HEE was initial estimates of budget impact analysis.
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Objectives: CONITEC has recommended for incorporation part of the technolo-
gies analyzed. Among the requested documents, applicants must provide a Health 
Economic Evaluation (HEE) under the SUS perspective, including an incremental 
cost-effectiveness ratio (ICER). However in the legal documents there is no explicit 
recommendation on the use of ICER and cost-effectiveness threshold (CET) as a 
criteria for technology recommendation. To analyze the CONITEC reports that 
recommended the incorporation of the technologies in the SUS from July 2012 to 
April 2015, and compare the values of the ICERs with CETs suggested in the litera-
ture. MethOds: Descriptive study, based on the reports available at the CONITEC 
website from July 2012 to April 2015. Reports were classified according to: type of 
technology, type of applicant, type of report, presence of HEE, and the type of HEE. 
ICER was compared with the CET recommended by WHO and Center of Health 
Economics (CHE)-University of York. Results: Seventy-two reports recommended 
the incorporation of the technology in the SUS. The most common technologies 
recommended were drugs (51.4%), procedures (30.6%) and materials (8.3%). The 
major applicant was the Public Health System (70.8%), followed by the pharmaceuti-
cal industry (8.3%). Most reports were classified as Technology Description (65.3%), 
followed by Rapid Review (19.4%), Mini Health Technology Assessment (8.3%), and 
only 6.9% the reports were Full HTA. Fifty-five reports conducted HEE, 80% (n = 
44) were partial and 20% (n = 11) were full. Of the Seventy-two technologies rec-
ommended for incorporation, only 8(11.1%) presented a full HEE with ICER. Seven 
technologies presented ICER below the CET proposed by WHO and only one below 
the CET proposed by CHE. cOnclusiOns: Most of the technologies recommended 
for incorporation were demanded by the Public Health System and were based on 
Technology Descriptions and Rapid Reviews. Use of a CET was not an essential 
criterion for recommending technology incorporation.
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intROductiOn: Egypt healthcare system shows high Out-Of-Pocket (OOP) expendi-
ture on health (72% of THE), with 40% of total OOP dedicated to pharmaceuticals. 
In an attempt to maintain patient access to affordable medicines, the Egyptian 
Ministry of Health (MoH) implements a strict pricing policy for pharmaceuticals. 
However, the current pricing system has some drawbacks and challenges. These 
challenges often cause delays in launch of some innovative medicines, shortage 
in some important medicines and dissatisfaction of the pharmaceutical industry 
about the low prices that put a great pressure on their operational sustainabil-
ity. Consequently the MoH decided to introduce some reform actions to address 
these problems, aiming to achieve fair pricing policy, using the differential pricing 
concept. Objectives: To explore different Methods of differential pricing within 
a country, to evaluate their applicability for Egypt by taking into account the inter-
national price referencing framework, and to provide recommendations for fair 
pricing of pharmaceuticals in Egypt. MethOds: A focus group of decision makers 
and industry experts was established to discuss the possible pricing options within 
the Egyptian healthcare system context and develop core assumptions before pre-
paring a draft report. The recommendations were developed by using the Quasi-
Delphi method. Results: Innovative pricing models, like differential pricing with 
confidential agreements, are expected to 1) shift the financial burden of pharma-
ceuticals’ price to the more affluent consumers and distribute the cost of innovation 
across the patients according to their socio-economic status, and 2) reduce negative 
externalities related to the international reference pricing system. cOnclusiOns: 
Differential pricing with confidential agreements would achieve a win-win situa-
